Doripenem in the Treatment of Complicated Intra-Abdominal Infections
Study Details
Study Description
Brief Summary
The purpose of this study is to compare the clinical response rate of doripenem versus a comparator in the treatment of hospitalized patients with complicated intra-abdominal infections.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 3 |
Detailed Description
Doripenem is an antibiotic medication not yet approved by the US FDA. This is a phase 3, multicenter, prospective, randomized, double-blind study of doripenem versus comparator antibiotic to assess the effectiveness and safety of doripenem in the treatment of complicated intra-abdominal infections in hospitalized adults. Doripenem or comparator is administered. The primary endpoint is the clinical response measured at late follow-up visit. The patients will receive either doripenem or comparator; treatment duration is 5 to 14 days.
Study Design
Outcome Measures
Primary Outcome Measures
- The clinical response measured at late follow-up visit. []
Secondary Outcome Measures
- The clinical response at early follow-up visit. Microbiological response at both early and late follow-up visits. Safety assessment (adverse events, changes in vital signs, laboratory test results) conducted throughout the study. []
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Has a requirement for surgical intervention within 24 hours of study entry
-
Requirement of antibacterial therapy in addition to surgical intervention in certain intra-abdominal infections
Exclusion Criteria:
-
Female patients who are pregnant, nursing, or if of child bearing potential not using a medically accepted, effective method of birth control
-
Any rapidly-progressing disease or immediately life-threatening illness
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Peninsula Pharmaceuticals, Inc.
Investigators
- Study Director: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- CR005389